Alzheimer disease trials in Portugal
8 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
- Where
- Coimbra, Guimaraes, Lisbon, Senhora Da Hora, Torres Vedras
- Age
- 55 years to 90 years
- People
- 426 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07011732 · EU 2025-520613-31-00 - No phaseTaking peopleInRAD Observational Study
- Where
- Porto
- Age
- 18 years and over
- People
- 50,000 worldwide
- Run by
- Stichting International Registry for Alzheimer's Disease and other Dementias Foundation
See details and how to joinNCT07213700 - Phase 3Taking peopleA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Where
- Guimaraes, Lisbon, Senhora Da Hora, Torres Vedras
- Age
- 55 years to 90 years
- People
- 406 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00 - Phase 3Taking peopleOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
- Where
- Lisbon
- Age
- 55 years to 90 years
- People
- 1,000 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00 - Phase 3Taking peopleA Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
- Where
- Coimbra, Guimaraes, Lisbon, Senhora Da Hora, Torres Vedras
- Age
- 55 years to 90 years
- People
- 650 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06937229 · EU 2024-519994-20-00 - Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
- Where
- Braga, Coimbra, Guimaraes, Porto, Senhora Da Hora, Torres Vedras
- Age
- 60 years to 85 years
- People
- 586 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06976203 · EU 2025-520747-32-00 - Phase 2Taking peopleA Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
- Where
- Guimaraes, Lisbon, Torres Vedras
- Age
- 55 years to 90 years
- People
- 300 worldwide
- Run by
- MapLight Therapeutics
See details and how to joinNCT06887192 · EU 2024-519820-26-00 - Phase 2Enrolling by invitationAn Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
- Where
- Guimaraes, Lisbon, Torres Vedras
- Age
- 55 years to 91 years
- People
- 210 worldwide
- Run by
- MapLight Therapeutics
See details and how to joinNCT07459660 · EU 2025-521757-16-00